Participant Age Range
18 years and older
“Medical Events of Interest and Health-Related Quality of Life in Chronic Lymphocytic Leukemia Patients Initiating Treatment with Bruton’s Tyrosine Kinase Inhibitors Acalabrutinib or Ibrutinib”
Data will be collected from CLL patients in the US who initiated acalabrutinib mono or combination therapy with an anti-CD20 monoclonal antibody (mAb) or ibrutinib mono- or combination therapy with an anti-CD20 mAb within 7 days (before or after) of study enrollment. The study will include both first line of therapy (1LOT) and relapsed/refractory (r/r) CLL patients.